Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belcesiran Phase 1 SAD in Healthy Volunteers
NCT04174118Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2019
- Primary completion
- Jul 2021
- Modality
- Gene Editing, Antisense DNA, Gene Silencing
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in alpha-1 antitrypsin deficiency (AATD) comparing Belcesiran with Placebo (2 arms). Primary endpoints: Safety and tolerability at 2 months, Evaluating safety and tolerability through physical exams at 2 months and 1 more. Started Oct 2019; status: completed.
02
Drugs
belcesiran
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT04174118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04174118.